| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
MV1 targets the inhibitor of apoptosis proteins (IAPs), specifically binding to their baculovirus IAP repeat (BIR) domains. By binding to these domains, MV1 disrupts the anti-apoptotic function of IAPs, promoting programmed cell death. This mechanism involves the induction of auto-ubiquitination activity and rapid proteasomal degradation of c-IAP. Additionally, MV1 binds to the HaloTag ligand, allowing for selective protein knockdown of HaloTag fusion proteins.
|
|---|---|
| ln Vitro |
MV1 (0.08 – 20 μM; 24 hours) prevents the development of EVSAT cells [1]. In MDA-MB-231 cells, MV1 (5 μM; 0–60 min) treatment causes c-IAP1 and c-IAP2[1]. Treatment with MV1 (5 μM; 1 hour) causes the degradation of c-IAP1 and c-IAP2, which is independent of caspase activation and dependent on proteosomal processes [1].
MV1 (0.08-20 μM; 24 hours) prevents the development of EVSAT cells. In MDA-MB-231 cells, it induces apoptosis by antagonizing IAP function. The compound's ability to promote programmed cell death makes it a valuable tool for studying apoptosis and cancer biology. As an IAP antagonist, it sensitizes cells to apoptotic stimuli. |
| ln Vivo |
In vivo studies with MV1 are limited, as the compound is primarily used as a research tool in cell-based assays. As an IAP antagonist, MV1 has the potential to promote apoptosis in vivo, which could be useful for studying tumor growth and response to therapy. However, detailed in vivo efficacy data are not widely available.
|
| Enzyme Assay |
In vitro assays for MV1 involve measuring its binding to IAP proteins and its ability to induce apoptosis. Binding assays typically use recombinant IAP proteins (e.g., XIAP, c-IAP1, c-IAP2) and measure the displacement of fluorescently labeled peptides or small molecules. Apoptosis assays involve treating cells with MV1 and measuring caspase activation, Annexin V staining, or DNA fragmentation. IC50 values for IAP binding are determined from competition binding curves.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: EVSAT cells Tested Concentrations: 0.08-20 μM Incubation Duration: 24 hrs (hours) Experimental Results: The IC50 value of EVSAT cells is 5 μM. Western Blot Analysis[1] Cell Types: MDA-MB-231 Cell Tested Concentrations: 5 μM Incubation Duration: 0-60 minutes Experimental Results: demonstrated a decrease in c-IAP1 and 2 protein levels within two minutes of exposure. Cellular assays for MV1 are performed using cancer cell lines (e.g., MDA-MB-231, EVSAT cells). Cells are treated with MV1 at concentrations ranging from 0.08 to 20 μM for 24 hours. Apoptosis is assessed by measuring caspase-3/7 activity, Annexin V staining, or TUNEL assay. Cell viability is measured using MTT or CellTiter-Glo assays. For protein knockdown experiments, cells expressing HaloTag fusion proteins are treated with MV1, and protein levels are assessed by Western blotting. |
| Animal Protocol |
In vivo animal studies with MV1 are limited. As a research compound, it is not typically administered to animals for therapeutic studies. If used, it would likely be administered via intraperitoneal or intravenous injection in mouse xenograft models to assess its effects on tumor growth. Detailed dosing regimens and protocols are not widely available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for MV1 are limited. Its molecular weight is approximately 675.84 g/mol. The compound is soluble in DMSO at ≥125 mg/mL. For in vitro studies, it is typically dissolved in DMSO and diluted in cell culture medium. Its oral bioavailability and metabolic stability have not been characterized.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for MV1 are limited. In cell-based assays, the compound shows activity at concentrations up to 20 μM. No significant cytotoxicity has been reported at the doses used for apoptosis studies. The compound is intended for laboratory research only and should be handled with standard safety precautions.
|
| References |
|
| Additional Infomation |
1-{(2S)-2-cyclohexyl-2-[(N-methyl-L-alanyl)amino]acetyl}-L-prolyl-β-phenyl-L-phenylalanine methyl ester is a tetrapeptide and an IAP antagonist. It functions as an IAP antagonist. It is a methyl ester and also a tetrapeptide.
MV1 is a research compound used as a pharmacological tool to study apoptosis and protein function. Its ability to antagonize IAPs and promote apoptosis makes it valuable for cancer research and the study of cell death pathways. Additionally, its HaloTag ligand-binding activity allows for the selective protein knockdown of HaloTag-fused proteins. MV1 is not approved for clinical use and is intended for laboratory research only. |
| Molecular Formula |
C33H44N4O5
|
|---|---|
| Molecular Weight |
576.73
|
| Exact Mass |
576.331
|
| CAS # |
1001600-54-9
|
| PubChem CID |
23657865
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.25
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
42
|
| Complexity |
892
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)OC)NC
|
| InChi Key |
UUPZYAHONNHULX-CJBSCAABSA-N
|
| InChi Code |
InChI=1S/C33H44N4O5/c1-22(34-2)30(38)35-28(25-18-11-6-12-19-25)32(40)37-21-13-20-26(37)31(39)36-29(33(41)42-3)27(23-14-7-4-8-15-23)24-16-9-5-10-17-24/h4-5,7-10,14-17,22,25-29,34H,6,11-13,18-21H2,1-3H3,(H,35,38)(H,36,39)/t22-,26-,28-,29-/m0/s1
|
| Chemical Name |
methyl (2S)-2-[[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3,3-diphenylpropanoate
|
| Synonyms |
MV 1; MV-1; MV1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 125 mg/mL (~216.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7339 mL | 8.6696 mL | 17.3391 mL | |
| 5 mM | 0.3468 mL | 1.7339 mL | 3.4678 mL | |
| 10 mM | 0.1734 mL | 0.8670 mL | 1.7339 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
